||Ticagrelor, produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved f
||Clopidogrel, a P2Y12 receptor antagonist, decreases platelet aggregation.
||(S)-(+)-Clopidogrel hydrogen sulfate
||(S)-(+)-Clopidogrel hydrogensulfate, a selective, high-affinity P2Y12 receptor antagonist, suppressess fibrinogen binding to platelets and platelet adhesion and aggregation.
||(±) Clopidogrel hydrogen sulfate
||Clopidogrel, an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease
||Prasugrel is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL
||Ticlopidine hydrochloride is an effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
||Ivermectin is a glutamate-gated chloride channel (GluCls) activator, with antiparasitic activity.
||AF-353, an effective and orally bioavailable antagonist of the P2X3/P2X2/3 receptor, inhibits human and rat P2X3 (pIC50= 8.0).
||A-438079 hydrochloride is a potent and selective P2X7 receptor antagonist with pIC50 of 6.9.
||AZD1283 is an effective P2Y12 receptor antagonist (EC50: 3.0 ug/kg/min, binding IC50: 11 nM). AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced
||A-804598 is a competitive and selective P2X7 receptor antagonist (IC50: 10 nM, rat; 9 nM, mouse; 11 nM, human).
||A 740003 is an effective and specific P2X7 receptor antagonist (IC50: 18/40 nM, for rat/human). It can reduce nociception in animal models of persistent neuropathic and inflammato
||Allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM). Non-nucleotide ligand. Binds receptor outside of the helical bundle. Blocks inhibition of spontaneous contraction of rat and mo
||MRS2578, an effective P2Y6 receptor antagonist with IC50 of 37 nM, shows insignificant inhibition at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
||GW791343 HCl is aHCl salt form of GW791343, which is a non-competitive allosteric modulator of human P2X7 receptor inhibitor with pIC50 of 7.
||Prasugrel hydrochloride is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.
||Pyridoxal Phosphate is the active form of vitamin B6 and a coenzyme for many pyridoxal phosphate (PLP)-dependent enzymes. PLP is involved in numerous enzymatic transamination, deca
||HMA is an amiloride derivative, shown to inhibit TRPA1-mediated calcium signal (IC50: 35 µM). It is an inhibitor of the Na+/H+ exchanger (NHE), with Ki of 0.013-2.4 µM for variou
||Hederasaponin B has antiviral activity, via inhibiting the viral VP2 protein expression and blocking viral capsid protein synthesis.
||Gefapixant is a P2X3 receptor (P2X3R) antagonist with IC50 of ~30 nM at recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors.
||UDP disodium salt
||UDP is a specific agonist of the P2Y6 receptors (EC50 = 13 nM for human P2Y6), stimulating the production of inflammatory mediators, phagocytosis, and vasoconstriction. UDP also ac
||Diquafosol Tetrasodium is a P2Y2 receptor agonist that stimulates the secretion of mucins from ocular tissues Diquafosol tetrasodium improves tear film stability and visual functio
||A-317491 is a non-nucleotide P2X3 ( Ki: 22 nM) and P2X2/3 receptor (Ki: 9 nM) antagonist, which inhibits calcium flux mediated by the receptors.
||GW791343 is a P2X7 allosteric modulator.
||A 438079 is a potent, and selective antagonist of P2X7 receptor (pIC50: 6.9).
||A 839977 is a P2X7 selective antagonist and the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta. It blocks BzATP-evoked calci
||CE-224535 is an antagonist of P2X7 receptor.
||Elinogrel can be given orally and intravenously and has a strong anti-platelet effect.Elinogrel is an effective, direct acting, competitive, reversible platelet P2Y12 antagonist (I
||BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak
||P2X3 antagonist 34
||P2X3 antagonist 34 is a selective and orally active antagonist of P2X3 homotrimeric receptor (IC50s: 25 nM, 92 nM, and 126 nM for the human, rat, and guinea pig P2X3 receptor
||BX430 is used for chronic pain and cardiovascular disease and it is a potent and selective noncompetitive allosteric human P2X4 receptor channels antagonist with an IC50 of 0.54 μ
||Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
||Norgestimate metabolite Norelgestromin
||Norelgestromin is one of the active metabolites of norgestimate.It is a steroidal progestin used in contraceptive patches, where it is combined with the estrogen ethinyl estradiol.
||RO3 is a selective antagonist of homomeric P2X3 and heteromeric P2X2/3 receptor
||Prasugrel (Maleic acid)
||Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist and inhibits ADP-induced platelet aggregation. Prasugrel Maleic acid is a thienopyridine and prodrug.
||PSB-1114 tetrasodium shows >50-fold selectivity versus the P2Y4 (EC50: 9.3 μM) and P2Y6 (EC50: 7.0 μM) receptors. PSB-1114 tetrasodium is an effective, enzymatically stable, and
||Piperazine, 1-[(5-methyl-3-isoxazolyl)methyl]- (9CI)
||Piperazine, 1-[(5-methyl-3-isoxazolyl)methyl]- (9CI) is a P2Y12 inhibitor.
||PSB-12062 is a potent and selective antagonist of P2X4(IC50 of 1.38 μM for human P2X4).
||Opiranserin is a development as an injectable agent for the treatment of postoperative pain. Opiranserin is a non-opioid and non-NSAID analgesic candidate and is a dual antagonist
||Ticagrelor metabolite M5
||Ticagrelor metabolite M5 is a metabolite of Ticagrelor, the first reversible oral antagonist of P2Y12 receptor. Compared to Clopidogrel, Ticagrelor has faster and more consistent i